Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Drops By 84.0%

GlucoTrack, Inc. (NASDAQ:GCTKGet Free Report) was the target of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 37,508 shares, a decline of 84.0% from the January 29th total of 234,255 shares. Based on an average daily volume of 98,162 shares, the short-interest ratio is currently 0.4 days. Currently, 3.8% of the shares of the company are short sold. Currently, 3.8% of the shares of the company are short sold. Based on an average daily volume of 98,162 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, GlucoTrack presently has an average rating of “Sell”.

View Our Latest Stock Analysis on GCTK

Institutional Trading of GlucoTrack

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in shares of GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after buying an additional 4,085 shares during the period. Boothbay Fund Management LLC purchased a new stake in GlucoTrack in the 4th quarter worth approximately $52,000. Finally, Ikarian Capital LLC purchased a new stake in GlucoTrack in the 4th quarter worth approximately $177,000. Hedge funds and other institutional investors own 10.92% of the company’s stock.

GlucoTrack Trading Up 2.6%

Shares of GCTK stock opened at $1.58 on Thursday. GlucoTrack has a 1 year low of $1.44 and a 1 year high of $30.51. The firm has a fifty day moving average price of $3.05 and a 200-day moving average price of $4.98. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.53 and a quick ratio of 1.53. The company has a market cap of $1.60 million, a price-to-earnings ratio of -0.05 and a beta of 0.32.

GlucoTrack Company Profile

(Get Free Report)

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.

See Also

Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.